Thursday, 01 October 2020


GC Pharma, Vaxess team up for influenza vaccine smart release patch

17 October 2019 | News

The MIMIX smart release patch technology has demonstrated the capacity to enhance the efficacy of commercially available, FDA-approved influenza vaccines

image credit- asianmag.com

image credit- asianmag.com

South Korea headquartered GC Pharma, a leading manufacturer of influenza vaccines with a global reach, and US based Vaxess, an innovative biotechnology company developing the MIMIX smart release patch, have partnered to commercialize a highly effective, painless, and refrigeration-free flu vaccine in a new, convenient patch format.

The MIMIX smart release patch technology has demonstrated the capacity to enhance the efficacy of commercially available, FDA-approved influenza vaccines, as well as ease the distribution and administration to patients. The MIMIX smart release patch strengthens responses against both vaccine-included and drifted influenza strains through the use of sustained antigen presentation. This more accurately mimics a natural infection, thereby driving stronger, broader, and more durable HAI titers and influenza-specific T-cell responses. Moreover, immunization via the shelf-stable MIMIX patch simplifies delivery, patient administration, and compliance. Combining the GC Pharma influenza vaccine and Vaxess smart release patch technology creates a powerful partnership to commercialize a more effective vaccine that can be easily administered to everyone.

This partnership announcement comes just a few months after Vaxess announced a financing round led by The Engine and receipt of federal grant support for the development of the MIMIX flu smart release patch. Financial terms of the agreement were not disclosed.

 


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account